Growing evidence has indicated that genes of the SGOC metabolism can serve as prognostic markers and potential therapeutic targets for tumor treatment.32 To better understand the clinical application potential of the SGOC network in HNSCC, we developed a novel classifier of a 4-gene SGOC prognostic signature (PRT1, TBPL1, PLOD2, and SLC44A4). This evidence concerns the gene SLC44A4 and neoplasm.